Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Avillion LLP
Avillion LLP
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Finance
Avillion appoints Kathryn J. Gregory as Chief Business Officer
Regulatory
US FDA and EMA accept submission of BOSULIF for CML treatment
Applications seek to expand approved use of BOSULIF into first-line treatment based on positive results from Phase 3 head-to-head trial
Pharmaceutical
Nanobodies could lead to a new generation of biological drugs
Avillion signs clinical co-development agreement with Merck to advance Anti IL-17 A/F Nanobody in psoriasis
Finance
Avillion appoints Mark Weinberg as Chief Medical Officer
Mark Weinberg will be based in Chicago as CMO for co-developer and financier of late-stage pharmaceutical product candidates
Research & Development
Jarrod Longcor joins Avillion as Chief Business Officer
Will take responsibility for negotiating co-development agreements and financial investments
Research & Development
Dr Allison Jeynes-Ellis becomes Chief Executive at Avillion
Founding member of management team and formerly Chief Medical Officer at the company
Subscribe now